Emerging diagnostics and therapeutics for Alzheimer disease

Area of Science:

• Neurology
• Biomarker Technology
• Therapeutic Development

Background:

• Alzheimer disease (AD) is a leading cause of dementia globally, with limited effective interventions.
• Current strategies to slow or prevent AD progression have seen minimal success.
• Recent breakthroughs offer new avenues for diagnosis and treatment.

Purpose of the Study:

• To review the latest advances in biomarker technologies for AD diagnosis.
• To highlight recent therapeutic developments for AD treatment.
• To discuss the potential for disease-modifying strategies in AD care.

Main Methods:

• Review of recent literature on neuroimaging and fluid-based biomarkers for AD staging.
• Analysis of pathological roles of amyloid, tau, and neuroinflammation in AD.
• Evaluation of lessons learned from randomized controlled trials of AD therapies.

Main Results:

• Biomarkers now enable pathological staging of AD.
• Certain anti-amyloid antibodies show potential in slowing cognitive decline in early AD.
• New therapeutic targets are emerging that may modify AD pathogenesis.

Conclusions:

• Recent discoveries in biomarkers and therapies are transforming AD diagnosis and treatment.
• Disease-modifying treatments for AD are becoming a tangible reality.
• These advances promise improved patient outcomes and enhanced clinical care for Alzheimer disease.